NIH runs a grants culture: you propose your own project to broad parent announcements and are judged by peer-review study sections. There's no topic list to match — the question is which Institute (NIBIB, NHLBI, NCI…) your device serves, and whether a program officer sees a fit. Email one before you write; they answer.
Money is the other reason. Formal caps sit near the government-wide guidelines (Phase I roughly low-$300Ks, Phase II ~$2M), but NIH maintains a waiver topic list that lets many device and biotech budgets go meaningfully higher — multi-million Phase IIs exist. After the 2026 reauthorization, NIH reissued its parent announcements with the classic three standard due dates: September 5, January 5, April 5.
FDA formally accepts computational modeling and simulation (CM&S) as valid scientific evidence in device submissions, with credibility assessed under the ASME V&V 40 framework. Practically, that means the same simulations that de-risk your design — implant fatigue margins, blood-flow hemodynamics, RF heating in MRI, ultrasound fields — can, if built and validated to standard, become part of your 510(k) or PMA evidence package. NIH reviewers know this: proposals that include a credible modeling-and-validation plan read as regulatory-aware, not just clever.
FDA's guidance on computational modeling credibility (built on ASME V&V 40) means device simulation isn't just R&D — done properly, it's regulatory evidence. Implant stress, hemodynamics, MRI heating, acoustic fields: these studies need commercial-grade, validated tools. Ask us what an Ansys evaluation could cover for your device's V&V plan.
See if you qualify for an Ansys eval + engineering support at no cost How access works →Official sources for this guide: NIH SEED (small business programs) · FDA — computational modeling credibility guidance · Grants.gov. Figures change; always confirm on the official page before relying on them.
